Volume 9, Issue 9

Antibiotics, Dosing, and CFTR

In this issue:

Airway infections are a hallmark of cystic fibrosis, making antibiotic therapies a mainstay of CF treatment. While the fight against ABX resistance is ongoing, newer data are showing that commonly used dosing regimens may have to be altered to account for the particular pharmacodynamics in people with CF. How should ABX dosing be altered, and what additional effect might CFTR modulation have on dosing decisions?

That’s the topic Dr. Andrea Hahn, Assistant Professor of Pediatrics and an Infectious Disease Specialist at Children’s National Medical Center and George Washington University School of Medicine and Health Sciences, addresses in this eCysticFibrosis Review podcast. 

Learning objective:

  • Describe the appropriate dosing regimen of specific beta-lactam antibiotics in people with CF.
  • Identify which bacterial pathogens in people with CF are most likely to be affected by CFTR modulator therapy.  

Author:

Andrea Hahn, MD, MS
Andrea Hahn, MD, MS

Assistant Professor of Pediatrics 
Infectious Disease Specialist 
Children’s National Medical Center 
George Washington University School of Medicine and Health Sciences

Program Directors:

Noah Lechtzin, MD, MHA

Director, Adult Cystic Fibrosis Program
Associate Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, MD

Peter J. Mogayzel, Jr., MD, PhD

Professor of Pediatrics
Director, Cystic Fibrosis Center
Johns Hopkins University School of Medicine
Baltimore, MD

Donna Peeler, RN

Clinical Nurse 
Pediatric Clinic Coordinator 
Johns Hopkins Cystic Fibrosis Center 
Baltimore, MD

Length of activity:

0.5 hour Physicians
0.5 contact hour Nurses

Launch date: September 30, 2020
Expiration date: September 29, 2022